Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Thromboelastography in patients with severe sepsis: a prospective cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Haase, N, Ostrowski, SR, Wetterslev, J, Lange, T, Møller, MH, Tousi, H, Steensen, M, Pott, F, Søe-Jensen, P, Nielsen, J, Hjortrup, PB, Johansson, PI & Perner, A 2015, 'Thromboelastography in patients with severe sepsis: a prospective cohort study' Intensive Care Medicine, vol. 41, pp. 77-85. https://doi.org/10.1007/s00134-014-3552-9

APA

Haase, N., Ostrowski, S. R., Wetterslev, J., Lange, T., Møller, M. H., Tousi, H., ... Perner, A. (2015). Thromboelastography in patients with severe sepsis: a prospective cohort study. Intensive Care Medicine, 41, 77-85. https://doi.org/10.1007/s00134-014-3552-9

CBE

Haase N, Ostrowski SR, Wetterslev J, Lange T, Møller MH, Tousi H, Steensen M, Pott F, Søe-Jensen P, Nielsen J, Hjortrup PB, Johansson PI, Perner A. 2015. Thromboelastography in patients with severe sepsis: a prospective cohort study. Intensive Care Medicine. 41:77-85. https://doi.org/10.1007/s00134-014-3552-9

MLA

Vancouver

Author

Haase, Nicolai ; Ostrowski, Sisse Rye ; Wetterslev, Jørn ; Lange, Theis ; Møller, Morten Hylander ; Tousi, Hamid ; Steensen, Morten ; Pott, Frank ; Søe-Jensen, Peter ; Nielsen, Jonas ; Hjortrup, Peter Buhl ; Johansson, Pär I. ; Perner, Anders. / Thromboelastography in patients with severe sepsis : a prospective cohort study. In: Intensive Care Medicine. 2015 ; Vol. 41. pp. 77-85.

Bibtex

@article{0c5c986eed3c49f99cdfc7f47c530ff1,
title = "Thromboelastography in patients with severe sepsis: a prospective cohort study",
abstract = "PURPOSE: To investigate the association between consecutively measured thromboelastographic (TEG) tracings and outcome in patients with severe sepsis.METHODS: Multicentre prospective observational study in a subgroup of the Scandinavian Starch for Severe Sepsis/Septic Shock (6S) Trial (NCT00962156) comparing hydroxyethyl starch (HES) 130/0.42 vs. Ringer's acetate for fluid resuscitation in severe sepsis. TEG (standard and functional fibrinogen) was measured consecutively for 5 days, and clinical data including bleeding and death was retrieved from the trial database. Statistical analyses included Cox regression with time-dependent covariates and joint modelling techniques.RESULTS: Of 267 eligible patients, we analysed 260 patients with TEG data. At 90 days, 68 (26 {\%}) had bled and 139 (53 {\%}) had died. For all TEG variables, hypocoagulability according to the reference range was significantly associated with increased risk of death. In a linear model, hazard ratios for death were 6.03 (95 {\%} confidence interval, 1.64-22.17) for increased clot formation speed, 1.10 (1.04-1.16) for decreased angle, 1.09 (1.05-1.14) for decreased clot strength and 1.12 (1.06-1.18) for decreased fibrinogen contribution to clot strength (functional fibrinogen MA), showing that deterioration towards hypocoagulability in any TEG variable significantly increased the risk of death. Patients treated with HES had lower functional fibrinogen MA than those treated Ringer's acetate, which significantly increased the risk of subsequent bleeding [HR 2.43 (1.16-5.07)] and possibly explained the excess bleeding with HES in the 6S trial.CONCLUSIONS: In our cohort of patients with severe sepsis, progressive hypocoagulability defined by TEG variables was associated with increased risk of death and increased risk of bleeding.",
author = "Nicolai Haase and Ostrowski, {Sisse Rye} and J{\o}rn Wetterslev and Theis Lange and M{\o}ller, {Morten Hylander} and Hamid Tousi and Morten Steensen and Frank Pott and Peter S{\o}e-Jensen and Jonas Nielsen and Hjortrup, {Peter Buhl} and Johansson, {P{\"a}r I.} and Anders Perner",
year = "2015",
doi = "10.1007/s00134-014-3552-9",
language = "English",
volume = "41",
pages = "77--85",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Thromboelastography in patients with severe sepsis

T2 - a prospective cohort study

AU - Haase, Nicolai

AU - Ostrowski, Sisse Rye

AU - Wetterslev, Jørn

AU - Lange, Theis

AU - Møller, Morten Hylander

AU - Tousi, Hamid

AU - Steensen, Morten

AU - Pott, Frank

AU - Søe-Jensen, Peter

AU - Nielsen, Jonas

AU - Hjortrup, Peter Buhl

AU - Johansson, Pär I.

AU - Perner, Anders

PY - 2015

Y1 - 2015

N2 - PURPOSE: To investigate the association between consecutively measured thromboelastographic (TEG) tracings and outcome in patients with severe sepsis.METHODS: Multicentre prospective observational study in a subgroup of the Scandinavian Starch for Severe Sepsis/Septic Shock (6S) Trial (NCT00962156) comparing hydroxyethyl starch (HES) 130/0.42 vs. Ringer's acetate for fluid resuscitation in severe sepsis. TEG (standard and functional fibrinogen) was measured consecutively for 5 days, and clinical data including bleeding and death was retrieved from the trial database. Statistical analyses included Cox regression with time-dependent covariates and joint modelling techniques.RESULTS: Of 267 eligible patients, we analysed 260 patients with TEG data. At 90 days, 68 (26 %) had bled and 139 (53 %) had died. For all TEG variables, hypocoagulability according to the reference range was significantly associated with increased risk of death. In a linear model, hazard ratios for death were 6.03 (95 % confidence interval, 1.64-22.17) for increased clot formation speed, 1.10 (1.04-1.16) for decreased angle, 1.09 (1.05-1.14) for decreased clot strength and 1.12 (1.06-1.18) for decreased fibrinogen contribution to clot strength (functional fibrinogen MA), showing that deterioration towards hypocoagulability in any TEG variable significantly increased the risk of death. Patients treated with HES had lower functional fibrinogen MA than those treated Ringer's acetate, which significantly increased the risk of subsequent bleeding [HR 2.43 (1.16-5.07)] and possibly explained the excess bleeding with HES in the 6S trial.CONCLUSIONS: In our cohort of patients with severe sepsis, progressive hypocoagulability defined by TEG variables was associated with increased risk of death and increased risk of bleeding.

AB - PURPOSE: To investigate the association between consecutively measured thromboelastographic (TEG) tracings and outcome in patients with severe sepsis.METHODS: Multicentre prospective observational study in a subgroup of the Scandinavian Starch for Severe Sepsis/Septic Shock (6S) Trial (NCT00962156) comparing hydroxyethyl starch (HES) 130/0.42 vs. Ringer's acetate for fluid resuscitation in severe sepsis. TEG (standard and functional fibrinogen) was measured consecutively for 5 days, and clinical data including bleeding and death was retrieved from the trial database. Statistical analyses included Cox regression with time-dependent covariates and joint modelling techniques.RESULTS: Of 267 eligible patients, we analysed 260 patients with TEG data. At 90 days, 68 (26 %) had bled and 139 (53 %) had died. For all TEG variables, hypocoagulability according to the reference range was significantly associated with increased risk of death. In a linear model, hazard ratios for death were 6.03 (95 % confidence interval, 1.64-22.17) for increased clot formation speed, 1.10 (1.04-1.16) for decreased angle, 1.09 (1.05-1.14) for decreased clot strength and 1.12 (1.06-1.18) for decreased fibrinogen contribution to clot strength (functional fibrinogen MA), showing that deterioration towards hypocoagulability in any TEG variable significantly increased the risk of death. Patients treated with HES had lower functional fibrinogen MA than those treated Ringer's acetate, which significantly increased the risk of subsequent bleeding [HR 2.43 (1.16-5.07)] and possibly explained the excess bleeding with HES in the 6S trial.CONCLUSIONS: In our cohort of patients with severe sepsis, progressive hypocoagulability defined by TEG variables was associated with increased risk of death and increased risk of bleeding.

U2 - 10.1007/s00134-014-3552-9

DO - 10.1007/s00134-014-3552-9

M3 - Journal article

VL - 41

SP - 77

EP - 85

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

ER -

ID: 44718259